-
1
-
-
34548188788
-
Drug hepatotoxicity from a regulatory perspective
-
Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007; 11: 507-524.
-
(2007)
Clin Liver Dis
, vol.11
, pp. 507-524
-
-
Senior, J.R.1
-
2
-
-
0034424966
-
Drug-induced liver disease
-
Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000; 4: 73-96.
-
(2000)
Clin Liver Dis
, vol.4
, pp. 73-96
-
-
Zimmerman, H.J.1
-
3
-
-
0037126649
-
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States
-
Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954.
-
(2002)
Ann Intern Med
, vol.137
, pp. 947-954
-
-
Ostapowicz, G.1
Fontana, R.J.2
Schiodt, F.V.3
Larson, A.4
Davern, T.J.5
Han, S.H.6
-
4
-
-
41349087120
-
The role of early in vivo toxicity testing in drug discovery toxicology
-
Fielden MR, Kolaja KL. The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf 2008; 7: 107-110.
-
(2008)
Expert Opin Drug Saf
, vol.7
, pp. 107-110
-
-
Fielden, M.R.1
Kolaja, K.L.2
-
5
-
-
84862932616
-
Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?
-
Zhang M, Chen M, Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem Res Toxicol 2012; 25: 122-129.
-
(2012)
Chem Res Toxicol
, vol.25
, pp. 122-129
-
-
Zhang, M.1
Chen, M.2
Tong, W.3
-
6
-
-
0033771951
-
Concordance of the toxicity of pharmaceuticals in humans and in animals
-
Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000; 32: 56-67.
-
(2000)
Regul Toxicol Pharmacol
, vol.32
, pp. 56-67
-
-
Olson, H.1
Betton, G.2
Robinson, D.3
Thomas, K.4
Monro, A.5
Kolaja, G.6
-
7
-
-
77955341032
-
Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison
-
Ballet F. Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison. Gastroenterol Clin Biol 2010; 34: 348-350.
-
(2010)
Gastroenterol Clin Biol
, vol.34
, pp. 348-350
-
-
Ballet, F.1
-
8
-
-
18844373318
-
Role of metabolism in drug-induced idiosyncratic hepatotoxicity
-
Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325-361.
-
(2005)
Crit Rev Toxicol
, vol.35
, pp. 325-361
-
-
Walgren, J.L.1
Mitchell, M.D.2
Thompson, D.C.3
-
9
-
-
46249118651
-
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals
-
Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. HEPATOLOGY 2008; 47: 2003-2009.
-
(2008)
HEPATOLOGY
, vol.47
, pp. 2003-2009
-
-
Lammert, C.1
Einarsson, S.2
Saha, C.3
Niklasson, A.4
Bjornsson, E.5
Chalasani, N.6
-
10
-
-
75449112589
-
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
-
Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-620.
-
(2010)
HEPATOLOGY
, vol.51
, pp. 615-620
-
-
Lammert, C.1
Bjornsson, E.2
Niklasson, A.3
Chalasani, N.4
-
11
-
-
0035147506
-
Prediction of a new drug's potential to cause idiosyncratic reactions
-
Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Devel 2001; 4: 55-59.
-
(2001)
Curr Opin Drug Discov Devel
, vol.4
, pp. 55-59
-
-
Uetrecht, J.1
-
12
-
-
35748934487
-
The influence of drug-like concepts on decision-making in medicinal chemistry
-
Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007; 6: 881-890.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 881-890
-
-
Leeson, P.D.1
Springthorpe, B.2
-
13
-
-
77749315417
-
Lipophilicity in drug discovery
-
Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discovery 2010; 5: 235-248.
-
(2010)
Expert Opin Drug Discovery
, vol.5
, pp. 235-248
-
-
Waring, M.J.1
-
14
-
-
49849094738
-
Physiochemical drug properties associated with in vivo toxicological outcomes
-
Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008; 18: 4872-4875.
-
(2008)
Bioorg Med Chem Lett
, vol.18
, pp. 4872-4875
-
-
Hughes, J.D.1
Blagg, J.2
Price, D.A.3
Bailey, S.4
Decrescenzo, G.A.5
Devraj, R.V.6
-
15
-
-
65549132575
-
Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds
-
Peters JU, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem 2009; 4: 680-686.
-
(2009)
ChemMedChem
, vol.4
, pp. 680-686
-
-
Peters, J.U.1
Schnider, P.2
Mattei, P.3
Kansy, M.4
-
16
-
-
65449179589
-
Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability
-
Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 2009; 19: 2844-2851.
-
(2009)
Bioorg Med Chem Lett
, vol.19
, pp. 2844-2851
-
-
Waring, M.J.1
-
17
-
-
80051665573
-
FDA-approved drug labeling for the study of drug-induced liver injury
-
Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16: 697-703.
-
(2011)
Drug Discov Today
, vol.16
, pp. 697-703
-
-
Chen, M.1
Vijay, V.2
Shi, Q.3
Liu, Z.4
Fang, H.5
Tong, W.6
-
18
-
-
84879601164
-
-
US Food and Drug Administration. Liver Toxicity Knowledge Base (LTKB). Accessed October 30
-
US Food and Drug Administration. Liver Toxicity Knowledge Base (LTKB). http://www.fda.gov/ScienceResearch/BioinformaticsTools/LiverToxicityKnowledgeBase/ucm2024036.htm. Accessed October 30, 2012.
-
(2012)
-
-
-
19
-
-
77955362472
-
Developing structure-activity relationships for the prediction of hepatotoxicity
-
Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 2010; 23: 1215-1222.
-
(2010)
Chem Res Toxicol
, vol.23
, pp. 1215-1222
-
-
Greene, N.1
Fisk, L.2
Naven, R.T.3
Note, R.R.4
Patel, M.L.5
Pelletier, D.J.6
-
20
-
-
84879606847
-
-
R Foundation for Statistical Computing. R: a language and environment for statistical computing. Accessed October 30, 2012.
-
R Foundation for Statistical Computing. R: a language and environment for statistical computing. http://www.R-project.org/2011, Accessed October 30, 2012.
-
-
-
-
21
-
-
33745341752
-
Combinatorial QSAR modeling of P-glycoprotein substrates
-
de Cerqueira Lima P, Golbraikh A, Oloff S, Xiao Y, Tropsha A. Combinatorial QSAR modeling of P-glycoprotein substrates. J Chem Inf Model 2006; 46: 1245-1254.
-
(2006)
J Chem Inf Model
, vol.46
, pp. 1245-1254
-
-
de Cerqueira Lima, P.1
Golbraikh, A.2
Oloff, S.3
Xiao, Y.4
Tropsha, A.5
-
22
-
-
84869462906
-
A decade of toxicogenomic research and its contribution to toxicological science
-
Chen M, Zhang M, Borlak J, Tong W. A decade of toxicogenomic research and its contribution to toxicological science. Toxicol Sci 2012; 130: 217-228.
-
(2012)
Toxicol Sci
, vol.130
, pp. 217-228
-
-
Chen, M.1
Zhang, M.2
Borlak, J.3
Tong, W.4
-
23
-
-
84879602893
-
-
National Center for Toxicological Research. LTBS: Liver Toxicity Biomarker Study.Accessed October 30
-
National Center for Toxicological Research. LTBS: Liver Toxicity Biomarker Study. http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm079290.pdf Accessed October 30, 2012.
-
(2012)
-
-
-
24
-
-
62749161471
-
The liver toxicity biomarker study: phase I design and preliminary results
-
McBurney RN, Hines WM, Von Tungeln LS, Schnackenberg LK, Beger RD, Moland CL, et al. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol Pathol 2009; 37: 52-64.
-
(2009)
Toxicol Pathol
, vol.37
, pp. 52-64
-
-
McBurney, R.N.1
Hines, W.M.2
Von Tungeln, L.S.3
Schnackenberg, L.K.4
Beger, R.D.5
Moland, C.L.6
-
25
-
-
68149160053
-
Physicochemical drug properties associated with in vivo toxicological outcomes: a review
-
Price DA, Blagg J, Jones L, Greene N, Wager T. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin Drug Metab Toxicol 2009; 5: 921-931.
-
(2009)
Expert Opin Drug Metab Toxicol
, vol.5
, pp. 921-931
-
-
Price, D.A.1
Blagg, J.2
Jones, L.3
Greene, N.4
Wager, T.5
-
26
-
-
59149103599
-
Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies
-
Schnackenberg LK, Chen M, Sun J, Holland RD, Dragan Y, Tong W, et al. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol Appl Pharmacol 2009; 235: 25-32.
-
(2009)
Toxicol Appl Pharmacol
, vol.235
, pp. 25-32
-
-
Schnackenberg, L.K.1
Chen, M.2
Sun, J.3
Holland, R.D.4
Dragan, Y.5
Tong, W.6
-
27
-
-
77952718055
-
Risk factors for idiosyncratic drug-induced liver injury
-
Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010; 138: 2246-2259.
-
(2010)
Gastroenterology
, vol.138
, pp. 2246-2259
-
-
Chalasani, N.1
Bjornsson, E.2
-
28
-
-
33845874637
-
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
-
Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
-
(2007)
Lancet
, vol.369
, pp. 71-77
-
-
Padwal, R.S.1
Majumdar, S.R.2
-
29
-
-
84879607140
-
-
US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. Accessed October 30
-
US Food and Drug Administration. FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. Accessed October 30, 2012.
-
(2012)
-
-
-
30
-
-
0029090947
-
Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions
-
Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. HEPATOLOGY 1995; 22: 820-827.
-
(1995)
HEPATOLOGY
, vol.22
, pp. 820-827
-
-
Banks, A.T.1
Zimmerman, H.J.2
Ishak, K.G.3
Harter, J.G.4
-
31
-
-
0032173110
-
Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series
-
Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998; 93: 1563-1565.
-
(1998)
Am J Gastroenterol
, vol.93
, pp. 1563-1565
-
-
Riley, T.R.1
Smith, J.P.2
-
32
-
-
69949092077
-
3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity-molecular mechanisms and lessons for pharmacotoxicity
-
Borlak J. 3.3 Trovafloxacin: a case study of idiosyncratic or iatrogenic liver toxicity-molecular mechanisms and lessons for pharmacotoxicity. Hum Exp Toxicol 2009; 28: 119-121.
-
(2009)
Hum Exp Toxicol
, vol.28
, pp. 119-121
-
-
Borlak, J.1
-
33
-
-
35848933222
-
Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system
-
Sun Q, Zhu R, Foss FW Jr, Macdonald TL. Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. Bioorg Med Chem Lett 2007; 17: 6682-6686.
-
(2007)
Bioorg Med Chem Lett
, vol.17
, pp. 6682-6686
-
-
Sun, Q.1
Zhu, R.2
Foss Jr, F.W.3
Macdonald, T.L.4
|